SAB Biotherapeutics Inc
SABSW0.031USD
-0.000-0.64%
Close （ET）Quotes delayed by 15 min
0.00Market Cap
--P/E TTM
More Details of SAB Biotherapeutics Inc Company
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing fully human, multi- targeted, high-potency immunoglobulins (IgGs), without the need for human donors or convalescent plasma, to treat and prevent immune and autoimmune disorders. The Company's lead asset, SAB-142, targets type 1 diabetes (T1D) with a disease-modifying therapeutic approach. Using advanced genetic engineering and antibody science to develop Transchromosomic (Tc) Bovine, the only transgenic animal with a human artificial chromosome, its DiversitAb drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, fully-human IgGs that can address a wide range of serious unmet needs in human diseases. The Company's SAB-176 pipeline program is a multivalent, broadly neutralizing -human polyclonal IgG therapeutic candidate in development for the treatment or prevention of severe influenza.
SAB Biotherapeutics Inc Info
Ticker SymbolSABSW
Company nameSAB Biotherapeutics Inc
IPO dateJan 12, 2021
CEOMr. Samuel J. Reich
Number of employees- -
Security typeCompany Warrant
Fiscal year-end- -
Address777 W 41St St
CityMIAMI BEACH
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code33140
Phone13058452813
Websitehttps://www.sab.bio/
Ticker SymbolSABSW
IPO dateJan 12, 2021
CEOMr. Samuel J. Reich
Company Executives of SAB Biotherapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Erick J. Lucera
Mr. Erick J. Lucera
Independent Director
Independent Director
--
--
Mr. David Link
Mr. David Link
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
--
--
Mr. Samuel J. Reich
Mr. Samuel J. Reich
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Mr. Andrew D. Moin
Mr. Andrew D. Moin
Independent Director
Independent Director
--
--
Ms. Katie Katherine Ellias
Ms. Katie Katherine Ellias
Independent Director
Independent Director
--
--
Dr. Alexandra Kropotova, M.D.
Dr. Alexandra Kropotova, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Christoph Bausch, Ph.D.
Dr. Christoph Bausch, Ph.D.
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Eddie J. Sullivan, Ph.D.
Dr. Eddie J. Sullivan, Ph.D.
President, Director
President, Director
--
--
Dr. Jay S. Skyler, M.D.
Dr. Jay S. Skyler, M.D.
Independent Director
Independent Director
--
--
Ms. Lucy To
Ms. Lucy To
Chief Financial Officer
Chief Financial Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Erick J. Lucera
Mr. Erick J. Lucera
Independent Director
Independent Director
--
--
Mr. David Link
Mr. David Link
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
--
--
Mr. Samuel J. Reich
Mr. Samuel J. Reich
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Mr. Andrew D. Moin
Mr. Andrew D. Moin
Independent Director
Independent Director
--
--
Ms. Katie Katherine Ellias
Ms. Katie Katherine Ellias
Independent Director
Independent Director
--
--
Dr. Alexandra Kropotova, M.D.
Dr. Alexandra Kropotova, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholder Types
Shareholders
Proportion
Other
100.00%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
16
907.26K
0.00%
-228.94K
2025Q3
14
798.53K
0.00%
-351.86K
2025Q2
14
801.24K
0.00%
-370.75K
2025Q1
19
861.24K
0.00%
-692.90K
2024Q4
19
878.36K
0.00%
-393.43K
2024Q3
22
619.45K
0.00%
-964.16K
2024Q2
21
1.10M
0.00%
-536.80K
2024Q1
21
1.16M
0.00%
-565.92K
2023Q4
20
1.26M
0.00%
-536.70K
2023Q3
20
1.31M
0.00%
-12.73K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
LMR Partners LLP
539.59K
0%
--
--
Sep 30, 2025
Morgan Stanley & Co. LLC
146.44K
0%
--
--
Sep 30, 2025
Yakira Capital Management, Inc.
--
0%
-78.73K
-100.00%
Jun 30, 2025
Homrich Berg
--
0%
-60.00K
-100.00%
Jun 30, 2025
Walleye Trading, LLC
11.44K
0%
-20.43K
-64.11%
Sep 30, 2025
Wolverine Asset Management, LLC
1.81K
0%
-2.81K
-60.80%
Sep 30, 2025
UBS Financial Services, Inc.
23.41K
0%
+23.41K
--
Sep 30, 2025
Tower Research Capital LLC
--
0%
-48.00
-100.00%
Mar 31, 2025
Morgan Stanley Smith Barney LLC
--
0%
-2.50K
-100.00%
Jun 30, 2024
Susquehanna International Group, LLP
26.30K
0%
+26.30K
--
Sep 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of SAB Biotherapeutics Inc?
The top five shareholders of SAB Biotherapeutics Inc are:
LMR Partners LLP holds 539.59K shares, accounting for 0.00% of the total shares.
Morgan Stanley & Co. LLC holds 146.44K shares, accounting for 0.00% of the total shares.
Yakira Capital Management, Inc. holds 0.00 shares, accounting for 0.00% of the total shares.
Homrich Berg holds 0.00 shares, accounting for 0.00% of the total shares.
Walleye Trading, LLC holds 11.44K shares, accounting for 0.00% of the total shares.
LMR Partners LLP holds 539.59K shares, accounting for 0.00% of the total shares.
Morgan Stanley & Co. LLC holds 146.44K shares, accounting for 0.00% of the total shares.
Yakira Capital Management, Inc. holds 0.00 shares, accounting for 0.00% of the total shares.
Homrich Berg holds 0.00 shares, accounting for 0.00% of the total shares.
Walleye Trading, LLC holds 11.44K shares, accounting for 0.00% of the total shares.
What are the top three shareholder types of SAB Biotherapeutics Inc?
The top three shareholder types of SAB Biotherapeutics Inc are:
Other
Other
How many institutions hold shares of SAB Biotherapeutics Inc (SABSW)?
As of 2025Q4, 16 institutions hold shares of SAB Biotherapeutics Inc, with a combined market value of approximately 907.26K, accounting for --% of the total shares. Compared to 2025Q3, institutional shareholding has increased by --.
What is the biggest source of revenue for SAB Biotherapeutics Inc?
In --, the -- business generated the highest revenue for SAB Biotherapeutics Inc, amounting to -- and accounting for --% of total revenue.
